Dermira Inc (DERM) SVP Christopher M. Griffith Sells 18,458 Shares

Dermira Inc (NASDAQ:DERM) SVP Christopher M. Griffith sold 18,458 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $27.05, for a total value of $499,288.90. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Dermira Inc (NASDAQ DERM) traded down $0.63 during trading hours on Thursday, reaching $28.08. The company had a trading volume of 992,008 shares, compared to its average volume of 759,267. Dermira Inc has a twelve month low of $21.35 and a twelve month high of $38.75. The firm has a market cap of $1,136.04, a price-to-earnings ratio of -4.51 and a beta of 0.80. The company has a quick ratio of 4.68, a current ratio of 4.68 and a debt-to-equity ratio of 1.40.

A number of equities research analysts have weighed in on DERM shares. Cantor Fitzgerald restated a “buy” rating and set a $45.00 price objective on shares of Dermira in a research note on Monday, November 6th. Zacks Investment Research lowered Dermira from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. Guggenheim started coverage on Dermira in a research note on Tuesday, December 5th. They set a “buy” rating for the company. Leerink Swann restated an “outperform” rating and set a $41.00 price objective (down previously from $47.00) on shares of Dermira in a research note on Tuesday, November 7th. Finally, Mizuho decreased their target price on Dermira from $43.00 to $39.00 and set a “buy” rating for the company in a research report on Tuesday, December 12th. Three research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $41.00.

A number of large investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN boosted its position in Dermira by 4.0% during the 3rd quarter. Wells Fargo & Company MN now owns 52,995 shares of the biopharmaceutical company’s stock valued at $1,431,000 after purchasing an additional 2,025 shares during the period. SG Americas Securities LLC boosted its position in Dermira by 66.8% during the 2nd quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 2,203 shares during the period. New York State Common Retirement Fund boosted its position in Dermira by 4.8% during the 3rd quarter. New York State Common Retirement Fund now owns 49,993 shares of the biopharmaceutical company’s stock valued at $1,350,000 after purchasing an additional 2,308 shares during the period. Quantbot Technologies LP boosted its position in Dermira by 75.4% during the 3rd quarter. Quantbot Technologies LP now owns 5,371 shares of the biopharmaceutical company’s stock valued at $145,000 after purchasing an additional 2,309 shares during the period. Finally, Legal & General Group Plc boosted its position in Dermira by 40.9% during the 2nd quarter. Legal & General Group Plc now owns 9,664 shares of the biopharmaceutical company’s stock valued at $281,000 after purchasing an additional 2,803 shares during the period. Institutional investors and hedge funds own 99.47% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Dermira Inc (DERM) SVP Christopher M. Griffith Sells 18,458 Shares” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/01/04/dermira-inc-derm-svp-christopher-m-griffith-sells-18458-shares.html.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Insider Buying and Selling by Quarter for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply